


## Damnacanthal

Cat. No.:	HY-108485
CAS No.:	477-84-9
Molecular Formula:	C <sub>16</sub> H <sub>10</sub> O <sub>5</sub>
Molecular Weight:	282.25
Target:	Src; Apoptosis; Fungal
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis; Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Damnacanthal is an anthraquinone isolated from the root of <i>Morinda citrifolia</i> . Damnacanthal is a highly potent, selective inhibitor of p56 <sup>lck</sup> tyrosine kinase activity. Natural Damnacanthal inhibits p56 <sup>lck</sup> autophosphorylation and phosphorylation of exogenous substrates with IC <sub>50</sub> s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against <i>Candida albicans</i> <sup>[1][2][3][4]</sup> .						
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 46 nM (p56 <sup>lck</sup> autophosphorylation) and 220 nM (phosphorylation of exogenous substrates by p56 <sup>lck</sup> ) <sup>[1]</sup> ; Apoptosis <sup>[2]</sup> ; <i>Candida albicans</i> <sup>[2]</sup>						
<b>In Vitro</b>	<p>Damnacanthal has &gt; 100-fold selectivity for p56<sup>lck</sup> over the serine/threonine kinases, protein kinase A and protein kinase C, and &gt; 40-fold selectivity for p56<sup>lck</sup> over four receptor tyrosine kinases. Damnacanthal also demonstrates modest (7-20-fold), but highly statistically significant, selectivity for p56<sup>lck</sup> over the homologous enzymes p60<sup>src</sup> and p59<sup>fyn</sup><sup>[1]</sup>.</p> <p>Damnacanthal (0.1-100 μM; 1-4 days; HCT-116 and SW480 cells) treatment results in a significant reduction of cell proliferation in a concentration- and time-dependent manner<sup>[2]</sup>.</p> <p>Damnacanthal (1-50 μM; 72 hours; HCT-116 cells) treatment results in a significant enrichment in the number of cells in the S/G1 and G2/G1 phases at concentration of 50 μM<sup>[2]</sup>.</p> <p>Damnacanthal (10 μM; 24 hours; HCT-116 cells) treatment significantly increases caspase 3/7 activity. Damnacanthal-induced apoptosis<sup>[2]</sup>.</p> <p>Damnacanthal (0.1-10 μM; 24 hours; HCT-116 cells) treatment induces NAG-1 expression in HCT-116 cells. Cyclin D1 expression is reduced at 10 μM of Damnacanthal, whereas p21 and p53 does not alter their expression. PARP cleavage is seen at 10 μM Damnacanthal treatment only in HCT-116 cells, where NAG-1 is induced<sup>[2]</sup>.</p> <p>Damnacanthal treatment for 2 weeks shows significant decreasing colony number in HCT-116 cells in a concentration-dependent manner. Damnacanthal-treated cells show a dramatic inhibition of clonogenic capacity. Damnacanthal-treated (1-50 μM; 48 hours) cells significantly inhibits the migration of HCT-116 cells in a concentration-dependent manner<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[2]</sup></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="border: none;">Cell Line:</td> <td style="border: none;">HCT-116 and SW480 cells</td> </tr> <tr> <td style="border: none;">Concentration:</td> <td style="border: none;">0.1 μM, 1 μM, 10 μM, 100 μM</td> </tr> <tr> <td style="border: none;">Incubation Time:</td> <td style="border: none;">1, 2, and 4 days</td> </tr> </table>	Cell Line:	HCT-116 and SW480 cells	Concentration:	0.1 μM, 1 μM, 10 μM, 100 μM	Incubation Time:	1, 2, and 4 days
Cell Line:	HCT-116 and SW480 cells						
Concentration:	0.1 μM, 1 μM, 10 μM, 100 μM						
Incubation Time:	1, 2, and 4 days						

Result:	Resulted in a significant reduction of cell proliferation in a concentration- and time-dependent manner.
Cell Cycle Analysis <sup>[2]</sup>	
Cell Line:	HCT-116 cells
Concentration:	1 $\mu$ M, 10 $\mu$ M and 50 $\mu$ M
Incubation Time:	72 hours
Result:	Resulted in a significant enrichment in the number of cells in the S/G1 and G2/G1 phases at concentration of 50 $\mu$ M.
Apoptosis Analysis <sup>[2]</sup>	
Cell Line:	HCT-116 cells
Concentration:	10 $\mu$ M
Incubation Time:	24 hours
Result:	Significantly increased caspase 3/7 activity.
Western Blot Analysis <sup>[2]</sup>	
Cell Line:	HCT-116 cells
Concentration:	0.1 $\mu$ M, 1 $\mu$ M and 10 $\mu$ M
Incubation Time:	24 hours
Result:	NAG-1 was induced in HCT-116 cells in a dose- and time-dependent manner. Cyclin D1 expression was reduced at 10 $\mu$ M.

#### In Vivo

Damnacanthal (10-100 mg/kg; oral administration; for 10-300 minutes; male ddY mice) treatment exhibits a significant antinociceptive effect in a dose-dependent manner in the formalin test. Administration of damnacanthal (100 mg/kg) shows significant inhibition of histamine-induced paw edema<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ddY mice (5-6 weeks) injected with formalin or Histamine <sup>[4]</sup>
Dosage:	10 mg/kg, 30 mg/kg and 100 mg/kg
Administration:	Oral administration; for 10 minutes, 30 minutes, 60 minutes or 300 minutes
Result:	Significantly reduced the growth of human lung tumor without acute toxicity.

## REFERENCES

- [1]. Faltynek CR, et al. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. *Biochemistry*. 1995 Sep 26;34(38):12404-10.
- [2]. Nualsanit T, et al. Damnacanthal, a noni component, exhibits antitumorigenic activity in human colorectal cancer cells. *J Nutr Biochem*. 2012 Aug;23(8):915-23.
- [3]. Aziz MY, et al. Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells. *Oncol Lett*. 2014 May;7(5):1479-1484.

---

[4]. Okusada K, et al. The antinociceptive and anti-inflammatory action of the CHCl<sub>3</sub>-soluble phase and its main active component, damnacanthal, isolated from the root of *Morinda citrifolia*. *Biol Pharm Bull.* 2011;34(1):103-7.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA